DexCom Stock
DexCom, Inc.
Company data
- Sector
- Healthcare
- Industry
- Medical - Devices
- Country
- United States
- CEO
- Jacob Steven Leach
- Employees
- 11,050
- Market cap
- $32.5 B
- IPO
- 14/04/2005
DexCom, Inc. (DXCM) is a specialized player in the healthcare / medical - devices industry, focusing on the development and commercialization of continuous glucose monitoring systems. The company offers comprehensive diabetes management solutions through models such as the Dexcom G6 as well as the pioneering Dexcom…
AI-generated company profile based on the figures on this page, last updated on 01/10/2026. Not investment advice.
DexCom stock: price history
1D
-1.9%
1W
+2.3%
1M
-1.5%
6M
+34.5%
YTD
+29.6%
1Y
+29.7%
2Y
+23.1%
5Y
-36.8%
10Y
+321.4%
Next earnings date
Next earnings date
29/10/2026 (in 12 days)
Volatility around earnings
~70% stronger price swings than usual
DexCom stock scores
- Valuation
Visible after free registration
- Trend
Visible after free registration
- Quality
Visible after free registration
- Dividend
Visible after free registration
- Growth
Visible after free registration
- Insider
Visible after free registration
- Earnings
Visible after free registration
- Revisions
Visible after free registration
- Sentiment
Visible after free registration
- Short Pressure
Visible after free registration
Register for free
Unlock all 11 scores
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Deterministically calculated from financial metrics, not investment advice. Updated nightly, last on 17/10/2026.
Business model & megatrends
Very robust business model with strong megatrend tailwind: wide moat, strong pricing power, predictable revenue.
3 more assignments (Enabler/Second row) Pro-only.
DexCom is a medical technology company specializing in the development and commercialization of continuous glucose monitoring systems. Its portfolio includes CGM systems such as the G6 and G7 series, as well as digital solutions like the Dexcom Real-Time API and the DexCom Share monitoring platform. The products serve diabetes management for patients as well as support for healthcare professionals, including endocrinologists and diabetologists. Through partnerships, the company also enables the integration of real-time data into external health applications.
- Revenue model
- Hardware sales
- Recurring revenue
- High
- Pricing power
- Strong
- Moat
- Wide
- Moat type
- Switching costs
- Capital intensity
- High
- Customer concentration
- Unknown
Ask the agents about DexCom
Analyst assessment of DexCom
PRICE TARGET LOW
US$77.00
CONSENSUS
US$96.14
MEDIAN
US$95.50
PRICE TARGET HIGH
US$115.00
1
STRONG BUY
41
BUY
8
HOLD
2
SELL
0
STRONG SELL
52
TOTAL · Buy
As of: 12/10/2026
DexCom stock metrics
P/E
33.22
P/B
12.59
EV/EBITDA
21.01
RETURN ON EQUITY
9.5%
NET MARGIN
19.0%
DEBT/EQUITY
0.53
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
99.6%
FLOAT SHARES
375,998,493
AVG. DAILY VOLUME (30D)
3,975,769
Insider transactions (SEC)
Stern Sadie
AUGUSTINOS NICHOLAS
AUGUSTINOS NICHOLAS
Brown Michael Jon
Sylvain Jereme M
Attention
Price since yesterday: -1.9%
Search (Google Trends)
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about DexCom stock
What does DexCom do?
DexCom, Inc. is a company in the Healthcare sector, Medical - Devices industry, headquartered in United States.
The CEO is Jacob Steven Leach, the company employs around 11,050 people.
The IPO was on 14/04/2005; the stock trades on NASDAQ under the ticker DXCM.
What do analysts say about DexCom stock?
52 analysts rate the stock, the consensus is Buy (as of 12/10/2026).
The average price target is US$96.14, ranging from US$77.00 to US$115.00, with a median of US$95.50.
This is an external assessment, not a statement by Market Jury.
When does DexCom report next?
The next earnings date is 29/10/2026.
Around past earnings, price swings were roughly 70% stronger than usual.
Does DexCom pay a dividend?
No, DexCom currently does not pay a dividend.
Which stocks are comparable to DexCom?
Comparable stocks include Abbott Laboratories, Stryker, Boston Scientific, Edwards Lifesciences, GE HealthCare Technologies, Zimmer Biomet Holdings, Align Technology and Bio-Rad Laboratories.
How can I get DexCom stock analyzed?
Clicking "Analyze stock" lets five strategies assess DexCom against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.